CSL Limited (ASX:CSL) reported a statutory net loss for the financial year ended 30 June 2026 after recognising significant non-cash impairments related to its Business portfolio. The company recorded a statutory net loss attributable to shareholders of US$2.6 billion, primarily due to Impairment charges.

Despite the statutory loss, CSL reported continued underlying profitability, supported by its plasma therapies business and ongoing cost management initiatives. The company said FY2026 represented a period of restructuring and business reset as it focused on improving operational performance and positioning the group for future growth.

FY2026 results reflect major impairment charges

CSL reported Revenue of approximately US$15.8 billion for FY2026, with the result affected by impairment charges and restructuring costs.

The company recognised approximately US$7.1 billion in pre-tax impairment charges, largely associated with CSL Vifor Assets acquired through the Acquisition of Vifor Pharma in 2022. The impairment reflected changes in the expected future cash flows of certain products and markets.

CSL stated that the impairment was a non-cash accounting adjustment and did not represent an immediate impact on the company’s operating cash generation.

The company reported underlying net profit after tax and Amortisation (NPATA) of approximately US$3.1 billion for FY2026, highlighting the difference between statutory results and underlying operating performance.

Plasma therapies remain the core business driver

CSL Behring, the company’s plasma-derived therapies division, remained the largest contributor to group revenue.

The division continued to benefit from Demand for immunoglobulin products, which are used in the treatment of a range of immune disorders.

CSL has been focused on improving plasma collection capacity, operational efficiency and Supply reliability after previous challenges across the plasma market.

The company has highlighted improving trends in immunoglobulin demand and continued Investment in plasma collection infrastructure as important areas for future growth.

CSL Vifor faces competitive pressures

The CSL Vifor business was the main contributor to FY2026 impairment charges.

CSL acquired Vifor Pharma in 2022 to expand its presence in iron deficiency and nephrology markets. Since the acquisition, the company has faced changes in market conditions, including increased competition affecting some products.

CSL has adjusted the carrying value of Vifor-related assets to reflect updated expectations for future performance.

The company continues to operate CSL Vifor as part of its broader portfolio, with a focus on managing costs, improving commercial execution and supporting key products.

Restructuring program targets efficiency improvements

CSL continued its transformation program during FY2026, aimed at simplifying operations and improving efficiency.

The program includes measures across the organisation, including changes to Manufacturing operations, Research and Development activities and commercial structures.

CSL reported progress on cost-saving initiatives during FY2026 and expects further benefits from the restructuring program over the following financial years.

The company has also been working to integrate parts of its commercial operations following the Vifor acquisition.

Seqirus separation remains under review

CSL has continued evaluating Options for its Seqirus influenza Vaccine business.

The company previously announced plans to separate Seqirus into a standalone business, although timing has remained dependent on market conditions and preparation activities.

Seqirus operates in the global influenza vaccine market, with performance influenced by seasonal demand, vaccination rates and public health conditions.

Further updates from CSL will determine the timing and structure of any potential separation process.

Balance sheet and Shareholder returns

Despite the statutory loss, CSL maintained its Dividend approach, reflecting its focus on shareholder returns and confidence in ongoing cash generation.

The company reported operating Cash Flow of approximately US$3.5 billion during FY2026.

CSL also announced a new share buyback program as part of its Capital management activities.

The company continues to focus on maintaining financial flexibility while investing in plasma collection, manufacturing capacity and business improvement initiatives.

FY2027 outlook and key priorities

CSL expects FY2027 performance to be supported by improvements in its core businesses, particularly CSL Behring.

The company has guided towards underlying NPAT growth of approximately 5% for FY2027 at constant currency.

Key priorities include maintaining growth in plasma therapies, delivering restructuring benefits, managing CSL Vifor performance and progressing strategic decisions around Seqirus.

What to watch next

Investors will continue to monitor CSL’s progress across several areas, including plasma collection trends, immunoglobulin demand, CSL Vifor performance and delivery of restructuring benefits.

Future financial updates will provide further insight into whether the company can translate operational improvements into sustained Earnings growth.

The pace of recovery across CSL’s businesses and execution of its strategic priorities will remain important factors shaping the company’s next phase.

Key Takeaways

CSL reported a statutory loss of approximately US$2.6 billion in FY2026 due to significant impairment charges.

Underlying earnings remained positive, supported by CSL Behring’s plasma therapies business and ongoing operational improvements.

The company is focused on restructuring, improving efficiency and managing challenges within CSL Vifor.

Future performance will depend on plasma growth, execution of cost initiatives and strategic decisions regarding Seqirus.